➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Colorcon
Mallinckrodt
Dow
Moodys

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 4,636,380

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,636,380
Title: Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
Abstract:A novel chemical method of labeling plasma proteins, compounds and substances containing proteins with the radionuclides of indium at physiologic pH 6-8 condition producing an efficiently labeled radioactive tracer material suitable for biomedical applications. These radiolabeled protein substances are not denatured by the labeling process but retain their native physiobiological properties. This novel labeling technique provides a simple and rapid means of labeling plasma proteins such as human serum albumin, transferrin, lactoferrin, fibrinogen, and immunoglobulin or antibodies with .sup.111 In or .sup.113m In for scintigraphic imaging which may allow visualization of thrombi, emboli, myocardial infarcts, infectious lesions, tumors or any vascular abnormalities in the body.
Inventor(s): Wong; Dennis W. (Torrance, CA)
Assignee:
Application Number:06/602,923
Patent Claims:see list of patent claims

Details for Patent 4,636,380

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Grifols Usa, Llc PLASBUMIN albumin (human) SOLUTION 101138 1 1994-09-26   Start Trial 2040-01-28 search
Baxalta Us Inc. FLEXBUMIN albumin human INJECTION, SOLUTION 101452 1 2014-07-31   Start Trial 2040-01-28 search
Csl Behring Ag ALBURX albumin (human) SOLUTION 102366 1 2009-01-06   Start Trial 2040-01-28 search
Grifols Usa, Llc ALBUTEIN albumin (human) INJECTION, SOLUTION 102478 1 2019-12-15   Start Trial 2040-01-28 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Boehringer Ingelheim
McKinsey
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.